Second-generation prophylactic HPV vaccines: successes and challenges

The role of HPV as the causative factor in cervical cancer has led to the development of the HPV vaccines Gardasil and Cervarix. These vaccines effectively protect against two HPV types associated with 70% of cervical cancer cases. Despite this success, researchers continue to develop second-generation HPV vaccines to protect against more HPV types and allow increased uptake in developing countries. While a reformulated vaccine based on the current technology is currently in clinical trials, another strategy consists of targeting highly conserved epitopes in the minor capsid protein of HPV, L2. Vaccines targeting L2 induce broadly neutralizing antibodies, capable of blocking infection by a wide range of HPV types. Several vaccine designs have been developed to optimize the display of L2 epitopes to the immune system and to reduce the cost of manufacture and distribution. L2-based vaccines show considerable promise as a potential next-generation HPV vaccine.

[1]  A. Psyrri,et al.  Molecular mechanisms of HPV induced carcinogenesis in head and neck. , 2014, Oral oncology.

[2]  D. Peabody,et al.  A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. , 2013, Vaccine.

[3]  E. Unger,et al.  Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. , 2013, The Journal of infectious diseases.

[4]  J. Fregnani,et al.  Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil , 2013, BMC Cancer.

[5]  S. Ottonello,et al.  Influence of Oxidation and Multimerization on the Immunogenicity of a Thioredoxin-L2 Prophylactic Papillomavirus Vaccine , 2013, Clinical and Vaccine Immunology.

[6]  J. Dillner,et al.  Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses , 2013, The Journal of investigative dermatology.

[7]  M. Jit,et al.  A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls , 2013, PloS one.

[8]  E. Rybicki,et al.  Development of human papillomavirus chimaeric L1/L2 candidate vaccines , 2013, Archives of Virology.

[9]  R. Roden,et al.  Optimization of Multimeric Human Papillomavirus L2 Vaccines , 2013, PloS one.

[10]  E. Domingo,et al.  Human Papillomavirus Type Distribution in Invasive Cervical Cancer and High-Grade Cervical Intraepithelial Neoplasia Across 5 Countries in Asia , 2013, International Journal of Gynecologic Cancer.

[11]  Bette C Liu,et al.  Fall in human papillomavirus prevalence following a national vaccination program. , 2012, The Journal of infectious diseases.

[12]  S. Garland,et al.  A review of clinical trials of human papillomavirus prophylactic vaccines. , 2012, Vaccine.

[13]  Wim Quint,et al.  The biology and life-cycle of human papillomaviruses. , 2012, Vaccine.

[14]  M. Schiffman,et al.  Updating the natural history of human papillomavirus and anogenital cancers. , 2012, Vaccine.

[15]  D. Peabody,et al.  VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human Papillomavirus , 2012, PloS one.

[16]  Peng Guan,et al.  Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer , 2012, International journal of cancer.

[17]  Jane J. Kim,et al.  Potential Benefits of Second-Generation Human Papillomavirus Vaccines , 2012, PloS one.

[18]  Chad K. Park,et al.  A Transmembrane Domain and GxxxG Motifs within L2 Are Essential for Papillomavirus Infection , 2012, Journal of Virology.

[19]  R. Roden,et al.  Development of AAVLP(HPV16/31L2) Particles as Broadly Protective HPV Vaccine Candidate , 2012, PloS one.

[20]  M. Plummer,et al.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. , 2012, The Lancet. Oncology.

[21]  D. Lowy,et al.  A Human Papillomavirus (HPV) In Vitro Neutralization Assay That Recapitulates the In Vitro Process of Infection Provides a Sensitive Measure of HPV L2 Infection-Inhibiting Antibodies , 2012, Clinical and Vaccine Immunology.

[22]  Jong-Sup Park,et al.  Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. , 2012, Vaccine.

[23]  L. Banks,et al.  Human Papillomavirus L2 Facilitates Viral Escape from Late Endosomes via Sorting Nexin 17 , 2012, Traffic.

[24]  K. Vinodhini,et al.  Prevalence and risk factors of HPV infection among women from various provinces of the world , 2012, Archives of Gynecology and Obstetrics.

[25]  P. Naud,et al.  Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine , 2012, Human vaccines & immunotherapeutics.

[26]  H. Synková,et al.  Transient expression of Human papillomavirus type 16 L2 epitope fused to N- and C-terminus of coat protein of Potato virus X in plants , 2012, Journal of Biosciences.

[27]  M. Einstein,et al.  Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years , 2011, Human vaccines.

[28]  R. Roden,et al.  A multimeric L2 vaccine for prevention of animal papillomavirus infections. , 2011, Virology.

[29]  J. Schiller,et al.  A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus Infection , 2011, Journal of Virology.

[30]  E. Franco,et al.  Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. , 2011, Preventive medicine.

[31]  D. Lowy,et al.  Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine , 2011, Journal of the National Cancer Institute.

[32]  D. Peabody,et al.  A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2 , 2011, PloS one.

[33]  N. Christensen,et al.  Cross-Neutralization Potential of Native Human Papillomavirus N-Terminal L2 Epitopes , 2011, PloS one.

[34]  L. Hammarstedt,et al.  Impact of HPV in Oropharyngeal Cancer , 2010, Journal of oncology.

[35]  L. Bruni,et al.  Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. , 2010, The Journal of infectious diseases.

[36]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[37]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[38]  D. Lowy,et al.  In vivo mechanisms of vaccine-induced protection against HPV infection. , 2010, Cell host & microbe.

[39]  R. Roden,et al.  Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. , 2010, Vaccine.

[40]  J. Schiller,et al.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. , 2010, Vaccine.

[41]  M. Stanley.  Pathology and epidemiology of HPV infection in females. , 2010, Gynecologic oncology.

[42]  Joakim Dillner,et al.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.

[43]  C. Wheeler,et al.  Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years , 2009, The Lancet.

[44]  J. Schiller,et al.  The role of furin in papillomavirus infection. , 2009, Future microbiology.

[45]  Y. Ishii,et al.  Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions. , 2009, Virology.

[46]  I. Carletti,et al.  Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years , 2009, Human vaccines.

[47]  R. Roden,et al.  Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines , 2009, Journal of Virology.

[48]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[49]  D. Lowy,et al.  Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines , 2009, Journal of the National Cancer Institute.

[50]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[51]  S. Ottonello,et al.  Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin. , 2009, Vaccine.

[52]  M. Ozbun,et al.  Two Highly Conserved Cysteine Residues in HPV16 L2 Form an Intramolecular Disulfide Bond and Are Critical for Infectivity in Human Keratinocytes , 2009, PloS one.

[53]  F. X. Bosch,et al.  Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. , 2008, Vaccine.

[54]  H. Yoshikawa,et al.  Modification of human papillomavirus‐like particle vaccine by insertion of the cross‐reactive L2‐epitopes , 2008, Journal of medical virology.

[55]  R. Roden,et al.  Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2 , 2008, Proceedings of the National Academy of Sciences.

[56]  Martin Müller,et al.  A Direct Comparison of Human Papillomavirus Type 16 L1 Particles Reveals a Lower Immunogenicity of Capsomeres than Viruslike Particles with Respect to the Induced Antibody Response , 2008, Journal of Virology.

[57]  B. Trus,et al.  Arrangement of L2 within the Papillomavirus Capsid , 2008, Journal of Virology.

[58]  D. Lowy,et al.  Mechanisms of Human Papillomavirus Type 16 Neutralization by L2 Cross-Neutralizing and L1 Type-Specific Antibodies , 2008, Journal of Virology.

[59]  I. Bossis,et al.  A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2 , 2007, Journal of Virology.

[60]  S. Franceschi,et al.  Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update , 2007, International journal of cancer.

[61]  P. Choyke,et al.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan , 2007, Nature Medicine.

[62]  B. Chackerian,et al.  Virus-like particles: flexible platforms for vaccine development , 2007, Expert review of vaccines.

[63]  Carole Fakhry,et al.  Case-control study of human papillomavirus and oropharyngeal cancer. , 2007, The New England journal of medicine.

[64]  R. Roden,et al.  A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. , 2007, Vaccine.

[65]  David A. Anderson,et al.  Virus-like particles: Passport to immune recognition , 2006, Methods.

[66]  F. Bray,et al.  Chapter 2: The burden of HPV-related cancers. , 2006, Vaccine.

[67]  D. Lowy,et al.  Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Y. Ishii,et al.  Human Papillomavirus 16 Minor Capsid Protein L2 Helps Capsomeres Assemble Independently of Intercapsomeric Disulfide Bonding , 2005, Virus Genes.

[69]  D. Lowy,et al.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. , 2004, Virology.

[70]  Y. Taketani,et al.  Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. , 2003, Vaccine.

[71]  N. Christensen,et al.  Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16 , 2003, Journal of Virology.

[72]  R. Karron,et al.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. , 2001, Journal of the National Cancer Institute.

[73]  D. Lowy,et al.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. , 2000, Virology.

[74]  G. Grindlay,et al.  Prophylactic and therapeutic vaccination against a mucosal papillomavirus. , 1993, The Journal of general virology.

[75]  R. Garcea,et al.  Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles , 1993, Journal of virology.

[76]  M. Hagensee,et al.  Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins , 1993, Journal of virology.

[77]  D. Lowy,et al.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[78]  Y. L. Lin,et al.  Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. , 1992, Virology.

[79]  N. Christensen,et al.  The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. , 1991, Virology.

[80]  M. Poljak,et al.  Human papillomavirus (HPV) prevalence and HPV type distribution in cervical, vulvar, and anal cancers in central and eastern Europe. , 2013, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

[81]  C. Wheeler,et al.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[82]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.

[83]  K. Palmer,et al.  Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. , 2006, Virology.